Streetbeat News

Regulatory

OCGN

Ocugen will host an in-person clinical showcase on November 12 to present updates on its retinal gene therapy trials, including Phase 3 liMeliGhT for retinitis pigmentosa and other trials. The event will also cover OCU200 for diabetic macular edema, with a Phase I trial starting soon.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 10:31 am

GSK

IDYA

IDEAYA Biosciences has received FDA clearance for a Phase 1 clinical trial of IDE275, a Werner Helicase development candidate. The trial will focus on patients with MSI-High tumors. IDEAYA will receive a $7 million payment for IND acceptance and potential future milestones up to $950 million. The company has a 50/50 US profit share and an 80/20 global R&D cost share with GSK.

Portfolio Pulse from Suganya Shanmugam

October 28, 2024 | 10:02 am

MCD

QSR

YUM

The U.S. copyright office has granted an exemption allowing third-party repairs of McDonald's ice cream machines, enabling franchise owners to bypass digital locks. This comes amid other challenges for McDonald's, including an E. Coli scare linked to its Quarter Pounder burgers.

Portfolio Pulse from Ananya Gairola

October 28, 2024 | 9:57 am

ITRM

Iterum Therapeutics has received FDA approval for ORLYNVAH™, the first-ever oral penem for treating uncomplicated urinary tract infections (uUTIs). This marks the first FDA-approved product for Iterum, targeting specific bacteria in adult women with limited treatment options.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 9:03 am

OILU

UCO

USO

XOP

Oil ETFs experienced a significant decline following Israel's military strikes on Iran, with ProShares Ultra Bloomberg Crude Oil (UCO) falling 8.41%, United States Oil Fund LP (USO) dropping 4.69%, SPDR S&P Oil & Gas Exploration & Production ETF (XOP) decreasing 1.81%, and MicroSectors Oil & Gas Exploration & Production 3X Leveraged ETNs (OILU) down 4.54%. Despite the geopolitical tensions, Iran's oil industry remains unaffected.

Portfolio Pulse from Pooja Rajkumari

October 28, 2024 | 9:00 am

BIIB

Biogen presented positive Phase 2 results for Felzartamab in treating IgA Nephropathy, showing stable kidney function and sustained effects. Felzartamab is a potential first-in-class treatment, with Phase 3 development planned.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 7:39 am

DTGHF

VLVLY

Volvo Group and Daimler Truck have signed a binding agreement to form a joint venture aimed at developing a software-defined vehicle platform and truck operating system. This initiative is set to revolutionize the commercial vehicle industry by enhancing safety, comfort, and efficiency. The joint venture will be headquartered in Gothenburg, Sweden, and is expected to be completed by the first half of 2025, pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 7:31 am

CCO

Clear Channel's planned sale of its Spanish business to JCDecaux has been canceled due to regulatory hurdles. The company will continue its operations in Spain and focus on its strategic priorities in America and Airports segments.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 6:46 am

TSLA

Tesla is offering a Cybertruck accessory, an off-road light bar, that customers must install themselves due to legal restrictions on Tesla employees. This comes as Tesla continues to innovate with the Cybertruck, despite facing regulatory challenges.

Portfolio Pulse from Benzinga Neuro

October 28, 2024 | 4:36 am

BTC-USD

El Salvador's President Nayib Bukele is celebrated as the world's most popular leader with high approval ratings, despite some controversies. His leadership, particularly in adopting Bitcoin as legal tender, has been praised by Elon Musk.

Portfolio Pulse from Aniket Verma

October 28, 2024 | 3:51 am